Trinity Biotech (TRIB) shares jumped 50% in recent Tuesday trading after the company said the latest pre-pivotal clinical trial for its continuous glucose monitoring technology yielded "breakthrough" results.
The modular device, described as "disruptively affordable and user-friendly," offers better signal quality and sensor performance, and a 25% to 30% enhancement in the key accuracy indicator compared with other previously released Waveform CGM sensors, the company said Tuesday in a statement.
The trial, which involved 30 diabetic participants, also showed that the patented device's low blood sugar reading accuracy achieved parity with industry benchmarks, the company said.
The company expects to complete further clinical trials for device enhancements and is scheduled to file for regulatory approval in the EU this year and in the US in 2026.
Price: 1.14, Change: +0.38, Percent Change: +50.13
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。